Pafolacianine Sodium Gets Priority Review for Ovarian Cancer Detection During Surgery
The Federal Drug Agency (FDA) has granted priority review status to a new drug; pafolacianine sodium. Priority status is granted to a new treatment, which has the potential to substantially improve the management of a pathological condition.
This drug is administered to patients immediately prior to surgery. Its effect is to bind to folate receptors commonly present in epithelial ovarian cancer cells. Once attached the presence of the drug is revealed under infrared light with fluorescence.
Imaging the revealed tumour cells enables more complete clearance of ovarian cancer at initial surgery, which will improve survival. Two Phase II trials have confirmed the efficacy of the drug, which could be a circuit breaker, with quicker and more effective surgery.
No comments:
Post a Comment